Skip Navigation
Menu Search
Sarcoma Center

In This Section      

Sarcoma Clinical Trials

Johns Hopkins Kimmel Cancer Center investigators lead or participate in a number of clinical trials. Here is a sampling of ongoing trials related to sarcomas, in which our investigators are studying new drug treatments, new drug combinations and new techniques in the management of sarcomas. Search our clinical trials directory. Our experts also participate in clinical trials through the Radiation Therapy Oncology Group.

Following is a description of some of our current studies:

J16167: Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
 
ACH1554: A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid Tumors
 
AEWS1221: Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
 
ARST1321: Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib
 
ARST1431: A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR)
 
J1768 SU2C-Sarc 032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab with Radiotherapy and Adjuvant Pembrolizumab in Patients with High-Risk, Localized Soft Tissue Sarcoma of the Extremity
 
J1781: A Randomized Phase 3 Trial OF TRC105 Aand Pazopanib versus Pazopanib alone in patietient with advanced Angiosarcoma
 
J1672: A phase 2-3, multicenter, Randomized, Double-Blind Study of selinexor (KPT-330) versus placebo in Patients with Advanced Unresectable Dedifferentiated Liposarcoma
 
NCTNA091401: Randomized Phase II Study of Nivolumab with or without Ipilimumab in Treating Patients with Metastatic or Unresectable Sarcoma
 
NCTNA091304: A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma
 
NCTNS1609: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
 
ETCTN10005: A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
 
ETCTN10015: A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma
 
J16138: Phase I Safety Study of Stereotactic Radiosurgery with Concurrent and Adjuvant PD-1 Antibody Nivolumab in Subjects with Recurrent or Advanced Chordoma
 
J1695: Phase 2 Study of Nivolumab in Solid tumors induced by Prior Radiation Exposure

 
 

Read Our Blogs

Cancer Matters timely topics
Our Cancer for caregivers